BYSI Stock — BeyondSpring Inc.: Cash, EV, Pipeline

Share price

$0.75

Market cap

$30.8M

Cash

$6.5M

Enterprise value

$24.3M

Balance sheet

Cash	$6.5M
Debt	$0.0M
Net cash	$6.5M
Enterprise value	$24.3M
Basic shares	41.1M shares
Fully diluted shares	43.9M shares
Fully diluted market cap	$32.9M
Cash per share	$0.16

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BYSI daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	Plinabulin	Phase 3	Non-Small Cell Lung Cancer; Non-squamous Non-Small Cell Lung Cance	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Plinabulin

Phase 3 · Active

Target microtubule

Partnerships Hengrui (via Wanchunbulin): exclusive commercialization and co-development in Greater China (mainland China, Hong Kong, Macau, Taiwan); RMB 200,000K (~$29.5M) upfront; up to RMB 700,000K (~$103.2M) regulatory milestones; up to RMB 400,000K (~$59.0M) commercial milestones; royalties on net sales with minimums

Indications

prevention of chemotherapy-induced neutropenia (CIN) (Phase 3)
2nd/3rd line non-small cell lung cancer (NSCLC) (Phase 3)

Status note Described as lead asset, a 'pipeline in a drug' in multiple cancer indications. FDA issued a Complete Response Letter in November 2021 on the NDA for plinabulin + G-CSF for prevention of CIN; company cites addressing CRL concerns as a key risk factor. TPD platform (SEED) classified as discontinued operations under a December 2024 divestiture plan.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Plinabulin
Lead indication	Non-Small Cell Lung Cancer
Lead phase	Phase 3
Active trials	1
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07361484	Phase 3	Not yet recruiting	Sponsor	BYSI	—	Non-Small Cell Lung Cancer; Non-squamous Non-Small Cell Lung Cance	—
NCT05130827	Phase 2	Active, not recruiting	Collaborator	Memorial Sloan Kettering Cancer Center	—	Multiple Myeloma	—
NCT05599789	Phase 2	Active, not recruiting	Collaborator	Peking Union Medical College Hospital	MRK	Non Small Cell Lung Cancer Metastatic	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for BeyondSpring Pharmaceuticals Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

BYSI — BeyondSpring Inc.